• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial.

作者信息

Liu Yizhen, Zhang Qunling, Lv Fangfang, Liu Xiaojian, Ji Dongmei, Xia Zuguang, Jin Jia, Tao Rong, Zhang Wenhao, Li Xiaoqiu, Zhang Shengjian, Wang Zezhou, Wang Jiachen, Hong Xiaonan, Cao Junning

机构信息

Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

Department of Hematology, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

出版信息

Blood Cancer J. 2025 Feb 25;15(1):24. doi: 10.1038/s41408-025-01229-5.

DOI:10.1038/s41408-025-01229-5
PMID:40000615
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11861983/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a0a/11861983/4d14a693cc5a/41408_2025_1229_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a0a/11861983/4d14a693cc5a/41408_2025_1229_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a0a/11861983/4d14a693cc5a/41408_2025_1229_Fig1_HTML.jpg

相似文献

1
Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial.来那度胺联合R-CHOP（R2-CHOP）治疗新诊断的双表达弥漫性大B细胞淋巴瘤：一项前瞻性II期临床试验。
Blood Cancer J. 2025 Feb 25;15(1):24. doi: 10.1038/s41408-025-01229-5.
2
RCHOP plus BTK inhibitor improves clinical outcomes in double expressor diffuse large B-cell lymphoma, unlike RCHOP plus lenalidomide.与利妥昔单抗联合来那度胺不同，利妥昔单抗联合布鲁顿酪氨酸激酶（BTK）抑制剂可改善双表达弥漫性大B细胞淋巴瘤的临床疗效。
Leuk Res. 2025 Jan;148:107622. doi: 10.1016/j.leukres.2024.107622. Epub 2024 Nov 9.
3
Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in China.来那度胺联合R-CHOP方案治疗中国弥漫性大B细胞淋巴瘤的成本效益分析
Front Pharmacol. 2024 Dec 16;15:1412743. doi: 10.3389/fphar.2024.1412743. eCollection 2024.
4
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.ROBUST：来那度胺联合 R-CHOP 与安慰剂联合 R-CHOP 治疗初治 ABC 型弥漫性大 B 细胞淋巴瘤的 III 期研究。
J Clin Oncol. 2021 Apr 20;39(12):1317-1328. doi: 10.1200/JCO.20.01366. Epub 2021 Feb 23.
5
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.在美国一项随机II期组间研究ECOG-ACRIN E1412中，来那度胺添加至R-CHOP方案可改善新诊断弥漫性大B细胞淋巴瘤的预后。
J Clin Oncol. 2021 Apr 20;39(12):1329-1338. doi: 10.1200/JCO.20.01375. Epub 2021 Feb 8.
6
Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.在一项新诊断的弥漫性大 B 细胞淋巴瘤老年患者中使用曲昔替丁加 R-CHOP 的 II 期研究中的临床疗效和分子生物标志物。
Clin Epigenetics. 2020 Oct 23;12(1):160. doi: 10.1186/s13148-020-00948-9.
7
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.来那度胺联合 R-CHOP 克服了新诊断弥漫性大 B 细胞淋巴瘤中非生发中心 B 细胞表型的不良预后影响：一项 II 期研究。
J Clin Oncol. 2015 Jan 20;33(3):251-7. doi: 10.1200/JCO.2014.55.5714. Epub 2014 Aug 18.
8
Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.接受R-DA-EPOCH/R-CHOP治疗的双表达/三表达弥漫性大B细胞淋巴瘤（DLBCL）患者的结局：单中心经验
Leuk Res Rep. 2021 Nov 29;16:100284. doi: 10.1016/j.lrr.2021.100284. eCollection 2021.
9
Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study.泽布替尼联合R-CHOP方案治疗新诊断的双表达淋巴瘤：一项2期临床研究。
Cancer. 2025 Jan 1;131(1):e35697. doi: 10.1002/cncr.35697.
10
Zanubrutinib plus R-CHOP improves the treatment effect of newly diagnosed diffuse large B cell lymphoma with double expression of MYC and BCL-2.泽布替尼联合R-CHOP方案可提高新诊断的MYC和BCL-2双表达弥漫性大B细胞淋巴瘤的治疗效果。
Front Immunol. 2025 Mar 12;16:1526318. doi: 10.3389/fimmu.2025.1526318. eCollection 2025.

本文引用的文献

1
Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study.来那度胺联合 R-CHOP 方案治疗滤泡性淋巴瘤转化的弥漫性大 B 细胞淋巴瘤新诊患者的疗效：来自 2 期 MC078E 研究的结果。
Blood Cancer J. 2021 Sep 25;11(9):160. doi: 10.1038/s41408-021-00542-z.
2
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.ROBUST：来那度胺联合 R-CHOP 与安慰剂联合 R-CHOP 治疗初治 ABC 型弥漫性大 B 细胞淋巴瘤的 III 期研究。
J Clin Oncol. 2021 Apr 20;39(12):1317-1328. doi: 10.1200/JCO.20.01366. Epub 2021 Feb 23.
3
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.具有治疗意义的弥漫性大 B 细胞淋巴瘤遗传亚型的概率分类工具。
Cancer Cell. 2020 Apr 13;37(4):551-568.e14. doi: 10.1016/j.ccell.2020.03.015.
4
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.来那度胺联合 R-CHOP21 方案治疗初治弥漫性大 B 细胞淋巴瘤（DLBCL）：来自两项 2 期临床试验联合分析的长期随访结果。
Blood Cancer J. 2018 Nov 8;8(11):108. doi: 10.1038/s41408-018-0145-9.
5
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.在德国高级非霍奇金淋巴瘤研究组的前瞻性临床试验中，针对弥漫性大 B 细胞淋巴瘤进行治疗，探讨了细胞起源分类和 MYC/BCL2 双表达状态的临床影响。
J Clin Oncol. 2017 Aug 1;35(22):2515-2526. doi: 10.1200/JCO.2016.70.3660. Epub 2017 May 19.
6
High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.伴有MYC和BCL2及/或BCL6重排的高级别B细胞淋巴瘤：双打击和三打击淋巴瘤以及双表达淋巴瘤。
Blood Rev. 2017 Mar;31(2):37-42. doi: 10.1016/j.blre.2016.09.004. Epub 2016 Sep 30.
7
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.《世界卫生组织淋巴组织肿瘤分类（2016年修订版）》
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.
8
Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.双打击和双蛋白表达淋巴瘤：侵袭性和难治性淋巴瘤。
Lancet Oncol. 2015 Nov;16(15):e555-e567. doi: 10.1016/S1470-2045(15)00005-4.
9
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.来那度胺联合 R-CHOP 克服了新诊断弥漫性大 B 细胞淋巴瘤中非生发中心 B 细胞表型的不良预后影响：一项 II 期研究。
J Clin Oncol. 2015 Jan 20;33(3):251-7. doi: 10.1200/JCO.2014.55.5714. Epub 2014 Aug 18.
10
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.来那度胺联合 R-CHOP21 方案治疗未经治疗的老年弥漫性大 B 细胞淋巴瘤患者：REAL07 开放标签、多中心、Ⅱ期临床试验结果。
Lancet Oncol. 2014 Jun;15(7):730-7. doi: 10.1016/S1470-2045(14)70191-3. Epub 2014 May 13.